Kincell Bio has raised $22M in a funding round led by NewSpring Capital. The funds will enhance its cGMP capabilities and support cell therapy development.

May 15, 2025•3 months ago

Amount Raised

$22 Million

DurhamBiotechnologyManufacturing

Investors

Kineticos Life SciencesNew Spring Capital

Description

Kincell Bio, a contract development and manufacturing organization, raised $22M in funding. The round was led by NewSpring Capital with participation from Kineticos Life Sciences. The company plans to use the funds to expand its cGMP capabilities and support innovative cell therapy companies. Pete Buzy has joined Kincell Bio’s Board of Directors as part of this funding.

Company Information

Company

Kincell Bio

Location

Durham, North Carolina, United States

About

Kincell Bio engineers cells into therapies. With manufacturing facilities located in Research Triangle Park, NC and Gainesville, FL, Kincell is a contract development and manufacturing organization (CDMO) situated in the United States. Kincell Bio’s mission is to streamline CMC development, with expertise in analytical and process development and GMP manufacturing, testing and release from early clinical to pivotal studies and product launch. Kincell Bio is focused on supporting innovative companies developing immune cell therapies, including autologous and allogeneic CAR-T, CAR-NK and CAR-M programs, as well as developing expertise in stem cell products and iPSCs.

Related People

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends